Biocept, Inc. (BIOC)

The chart shows the growth of $10,000 invested in Biocept, Inc. in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $0 for a total return of roughly -100.00%. All prices are adjusted for splits and dividends.

Biocept, Inc. had a return of -43.40% year-to-date (YTD) and -85.85% in the last 12 months. Over the past 10 years, Biocept, Inc. had an annualized return of -67.49%, while the S&P 500 had an annualized return of 9.32%, indicating that Biocept, Inc. did not perform as well as the benchmark.

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Biocept, Inc. Sharpe ratio is -1.12. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.

The Drawdowns chart displays portfolio losses from any high point along the way.

The table below shows the maximum drawdowns of the Biocept, Inc.. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Biocept, Inc. is 100.00%, recorded on Mar 17, 2023. The portfolio has not recovered from it yet.

Current Biocept, Inc. volatility is 258.63%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.